Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Operating Income (2016 - 2025)

Historic Operating Income for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $66.3 million.

  • Catalyst Pharmaceuticals' Operating Income rose 3016.76% to $66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.8 million, marking a year-over-year increase of 4874.43%. This contributed to the annual value of $195.1 million for FY2024, which is 12476.62% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Operating Income stood at $66.3 million for Q3 2025, which was up 3016.76% from $66.3 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Operating Income's 5-year high stood at $66.3 million during Q2 2025, with a 5-year trough of -$37.2 million in Q3 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Operating Income value was $30.8 million (recorded in 2022), while the average stood at $33.3 million.
  • Its Operating Income has fluctuated over the past 5 years, first plummeted by 24814.76% in 2023, then surged by 23689.63% in 2024.
  • Catalyst Pharmaceuticals' Operating Income (Quarter) stood at $12.7 million in 2021, then soared by 141.73% to $30.8 million in 2022, then surged by 35.36% to $41.7 million in 2023, then surged by 50.73% to $62.8 million in 2024, then grew by 5.45% to $66.3 million in 2025.
  • Its Operating Income stands at $66.3 million for Q3 2025, versus $66.3 million for Q2 2025 and $63.4 million for Q1 2025.